Allergan Settles Botox Off-Label Claims For $600M

Law360, New York (September 1, 2010, 3:01 PM EDT) -- Allergan Inc. reached a $600 million settlement with the U.S. Department of Justice on Wednesday to resolve criminal and civil claims stemming from the company's marketing of off-label uses for its blockbuster wrinkle-treating drug Botox.

Allergan has agreed to plead guilty to a misdemeanor misbranding charge and will cough up $375 million for a criminal fine and forfeiture, as well as $225 million to fund a civil settlement with the federal government and several states. The global settlement must be approved by the U.S. District Court...
To view the full article, register now.